Board of Directors
Hanns Pielenz
In Memoriam
Hanns A. Pielenz
Former President of Fibrotec Ventures, LLC
At Promedior, we continue to be inspired by and grateful to Hanns A. Pielenz, founder and former President of Fibrotec Ventures, LLC who served on Promedior's Board of Directors from 2012 until his death in 2013. In his time on Promedior's Board, his wisdom and thoughtfulness helped to guide and shape the company's plans and strategy.

When he was diagnosed with myelofibrosis in 2011, Hanns decided that his legacy would be to develop, fund, and coordinate medical, financial, and visionary business resources to find a cure for this serious, life-limiting disease. It was as part of this tireless quest that Hanns committed his company to a significant investment in Promedior and joined its Board.

We at Promedior are committed to our drug development programs in myleofibrosis and other serious fibrotic diseases, striving to ensure that Hanns' legacy will help advance potential treatments for patients in need.

Board of Directors

Nancy is the Executive Vice President and Chief Financial Officer of HAP Investment Group, LLC, a family office for the Hanns A. Pielenz family. In this role, she is active in sourcing, negotiating, and managing entrepreneurial investments in real estate in a variety of product types including multifamily, office and industrial; investments in all stages of venture capital; and investments in operating entities in diverse industries including health care.

Nancy serves on the board of directors of Parata Systems, a Durham, North Carolina pharmaceutical automation company, and is a co-founder and board member of Orsenix, LLC and Orsenix, BV – biotech startups. She is also a member of the board of trustees of St. Mary's School in Raleigh, North Carolina and serves on the Executive Committee and chairs the Investment Committee.

Nancy’s background is in banking and finance, and she was a partner in First Union's Private Capital Management Group and a Vice President with Wachovia Bank in both their commercial lending and real estate divisions prior to the formation of HAP Investment Group in 2000. She has a BS degree in Journalism and an MBA from the University of North Carolina in Chapel Hill.

Jason Lettmann joined Promedior’s board in 2014 and is the Company’s CEO. Jason is a General Partner of Lightstone Ventures as well as a General Partner on the Life Science team at Morgenthaler Ventures. Jason invests in biopharmaceutical and medical device companies and brings over 15 years of operating and venture experience in the life science sector. In addition to his role at Promedior, Jason serves on the Board of Directors of ALX Therapeutics Ltd., Carrick Therapeutics Ltd., Cerevance Inc, FIRE1 Ltd., Relievant Medsystems Inc., and Second Genome Inc.. Jason was previously a Director and led investments in Ra Pharmaceuticals (NASDAQ: RARX) and Vapotherm (NYSE: VAPO) as well as actively involved with Morgenthaler’s investments in Ardian (acquired by Medtronic), Cabochon Aesthetics (acquired by Ulthera), and Transcend Medical (acquired by Alcon). Jason established Lightstone’s Europe office in 2014 located in Dublin, Ireland, to expand the firm’s investment activities to Europe and currently serves as Director of Lightstone Capital Management Ireland Ltd.

Before joining Morgenthaler in 2009, Jason was a Vice President at Split Rock Partners where he focused on early-stage venture investments in medical devices and the life sciences. At Split Rock, Jason was actively involved with the firm’s investments in Atritech (acquired by Boston Scientific), Entellus Medical (NASDAQ: ENTL), and Evalve (acquired by Abbott) and a co-founder and on the Board of Tarsus Medical before its acquisition by Integra Life Sciences in 2013. Jason’s experience also includes tenure with Guidant Corporation’s Compass Group which focused on corporate venture investing and business development, as well as a consultant with Accenture’s Health and Life Science practice, where he advised clients across the medical device, pharmaceutical, and payer sectors. Jason also worked as a Genetic Research Analyst at the University of Iowa Hospitals and Clinics.

Jason has an M.B.A. with distinction from the University of Michigan’s Ross School of Business and a B.A. with honors from the University of Iowa.

Gus has been a Managing Director of HealthCare Ventures (HCV) since 2000. He has over 20 years of experience in the biotechnology industry in finance, business development, mergers and acquisitions, and general management. Prior to joining HCV, he was Chief Operating Officer of LeukoSite, Inc., a HealthCare Ventures III, IV, and V company, which was acquired by Millennium Pharmaceuticals. Before joining LeukoSite, he was Chief Financial Officer and Vice President of Corporate Development for Alpha-Beta Technology. He held similar positions at BioSurface Technology and Armstrong Pharmaceuticals. He was previously a management consultant with KPMG Peat Marwick. Gus received a Master's degree in Public and Private Management from Yale University.

Geert-Jan co-founded Forbion in 2006 and currently serves on the boards of several Forbion portfolio companies: AM-Pharma, Exosome Diagnostics Inc., Sanifit, NeRRe Therapeutics, and KaNDy Therapeutics. In 2004 he led the firm’s successful investment in bluebird bio (NASDAQ: BLUE), which went public in 2013, where he supported the company in clinical development and served as Chairman for several years. Other investments include Acorda Therapeutics (NASDAQ:ACOR), which went public in 2006, where he was part of the AMPYRA®(dalfampridine) board panel to evaluate a new clinical endpoint in Multiple Sclerosis; PanGenetics B.V., leading their Series B and sold to Abbott for $190 million in 2009; and Transave, where he supported the company’s clinical development for ARIKAYCE® (liposomal amikacin for inhalation) partly as interim Chief Medical Officer and serving on the board of directors until the merger with Insmed (NASDAQ:INSM) in 2010.

Prior to joining ABN AMRO Capital Life Sciences (Forbion’s predecessor) in 2001, Geert-Jan received his Medical Degree from the University of Utrecht (NL) and spent two years as a clinician in Obstetrics and Gynecology at the University Medical Center of Utrecht (UMC). He then joined Searle (now Pfizer) working in the field of Arthritis & Pain, involved in clinical development as well as in the European Advocacy Development for the pre-launch of Celebrex®.

After transitioning to Byk Gulden (now Takeda) he became Clinical Research Manager, where his department was responsible for the design and execution of numerous early and late stage clinical trials that formed the basis for two global product registrations, i.e. Daxas® and Alvesco® in the field of Respiratory Medicine (asthma and COPD). He was a member of the Global Medical Marketing group of their Respiratory Franchise and was involved in the line extension program for Pantozol®.

John is the Founding and Managing Partner of Easton Capital Group. He is also a Partner and Senior Advisor to Gore Range Capital. Prior to founding Easton Capital, John was the founder and Managing General Partner of Security Pacific Capital Investors – the $200 million private equity fund of the then fifth largest American bank’s merchant bank. Prior to Security Pacific, he was a Managing Director and Partner at E.M. Warburg, Pincus & Co., Inc., where he spent eight and a half years.

Previously, John was an attorney with Sullivan and Cromwell. In addition to Promedior, he currently serves on the boards of Trellis Bioscience, where he is Executive Chairman; Sequella; Sensoriant; Within3; and TigerText. He also co-founded Comverse Technology, which grew to $1.2 billion in sales. He has served as the Co-Chairman of the President's Council at the Cold Spring Harbor Laboratory and the Chairman of the Columbia University Medical Center Heath Sciences Advisory Council and as a Trustee of The New Museum of Contemporary Art. He holds a JD degree from Yale Law School and a BA degree, magna cum laude and Phi Beta Kappa, from Yale College.

An accomplished entrepreneur in the life sciences industry, Howard is currently Executive Chairman and co-founder of Sofregen, Inc., a commercial stage medical device company. Prior to Sofregen, he was the Chief Executive Officer and President of Seventh Sense Biosystems. He was also founder, Chairman and Chief Executive Officer of EKR Therapeutics, a specialty pharmaceutical company focused in the hospital critical care market, sold to Chiesi Pharma in 2012. Howard co-founded ESP Pharma where he served as a director in addition to the company's President and Chief Operating Officer until its sale to PDL Biopharma in 2005. He began his career in sales and marketing at Merck and Co., Inc. and later moved to Parke-Davis where he launched that company's diabetes franchise in 1997. Howard holds a BA degree in Chemistry from Rutgers University.


Promedior's mission is to develop and advance targeted therapeutics to address the significant unmet needs of patients with diseases involving fibrosis.